January 2025 – OCE ENGAGE – Project Community

Click to share this newsletter with your friends! Welcome to the January 2025 edition of the FDA Oncology Center of Excellence (OCE) quarterly newsletter from Project Community. This newsletter provides a summary of OCE’s upcoming public events, educational opportunities, and recent oncology product approvals. These are free and everyone is welcome. Watch for updates throughout 2025 and send your suggestions to OCE-Engagement@fda.hhs.gov. We thank all the patients and advocates who share their experiences

Read the full article here

Source: content.govdelivery.com

Categories: Oncologists1, General Medicine News

Tags: OCEProjectCommunity

Tweets with this article

FDA Oncology

Just posted! OCE ENGAGE - A Project Community Newsletter with news of interest to patients with cancer and advocates, healthcare providers, and families. Upcoming public meetings and profile of advocates. Sign up for free! https://t.co/gVip8JsQtZ #OCEProjectCommunity

Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma

This nonrandomized clinical trial in pediatric relapsed classic Hodgkin lymphoma tested fludeoxyglucose-18 positron emission tomography scans to identify patients in whom transplant-free salvage therapy would…

JAMA Oncology January 8, 2025

Amivantamab/Lazertinib Improves Survival in EGFR+ Advanced Lung Cancer

Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant NSCLC.

Oncology Nursing News January 8, 2025

C-Reactive Protein Induces Immunosuppression by Activating FcγR2B in Pulmonary Macrophages to Promote Lung Metastasis

CRP maintains host–commensal tolerance by inhibiting pulmonary macrophage activation and can be targeted to remodel the premetastatic niche in the lung to lower the risk…

Cancer Research January 8, 2025

AACR-QuadW Foundation Sarcoma Research Fellowship in Memory of Willie Tichenor

The one-year grant of $50,000 supports a postdoctoral or clinical research fellow conducting translational or clinical sarcoma research.

AACR January 8, 2025

Construction and Validation of a Novel Forecasting Nomogram to the Risk of Colorectal Adenomas: Preventing Colorectal Cancer at Its Origin

Colorectal adenomas are the origin of most colorectal cancers. In this research, we explored the risk factors of colorectal adenomas and constructed a colorectal adenoma…

Cancer Prevention Research January 8, 2025

High Incidence of Gastric Cancer in El Salvador: A National Multisectorial Study during 2000 to 2014

AbstractBackground:. Gastric adenocarcinoma is the fourth leading cause of global cancer mortality and leading infection-associated cancer. Gastric cancer has significant geographic variability, with a high…

Cancer Epidemiology, Biomarkers & Prevention January 8, 2025

MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer

The kinases MARK2 and MARK3 are identified as requirements for the function of the YAP and TAZ oncogenes, thus providing a druggable vulnerability in Hippo-dysregulated…

Cancer Discovery January 8, 2025

Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial

Liposome mitoxantrone monotherapy could induce a comparable objective response and progression-free survival compared to the approved new drugs, which could be considered a promising treatment…

ACS Journal Cancer January 8, 2025

Semantics Series—The Role of Common Data Elements and Artificial Intelligence | CBIIT

Common Data Elements (CDEs) enrich and standardize data through consistent and accurate metadata, helping to make data ready for use in training artificial intelligence (AI)…

National Cancer Institute January 8, 2025

Repurposed Drugs Pose an Ethical Challenge for Physicians

Knowing whether repurposing old drugs helps patients with cancer is important, but it will take a concerted investment by public entities such as the National…

Targeted Oncology January 8, 2025

Related Articles